The Impact of Tumor Mutation Burden on the Effect of Frontline Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric Cancers

BACKGROUND: Trastuzumab is a HER2-trargeted humanized monoclonal antibody that has been studied as a first-line treatment for patients with HER2-positive advanced gastric cancer (AGC). The effect of anti-HER2 therapy according to tumor mutational burden (TMB) in HER2-positive AGC remains unclear. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hye Ryeon, Ahn, Soomin, Jo, Hyunji, Kim, Hongsik, Hong, Joohyun, Lee, Jeeyun, Lim, Ho-Yeong, Kang, Won Ki, Kim, Seung Tae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674178/
https://www.ncbi.nlm.nih.gov/pubmed/34926309
http://dx.doi.org/10.3389/fonc.2021.792340

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674178/
https://www.ncbi.nlm.nih.gov/pubmed/34926309
http://dx.doi.org/10.3389/fonc.2021.792340

Ejemplares similares